Pharmaceuticals, Biotechnology and Life Sciences
One of India’s best-known whistleblowers, who exposed dangerous practices in the generic drug industry in 2013, is taking the country’s drugs regulators to court, accusing them of failing to enforce rules on drug safety in the $15 billion (11 billion pound) industry.
Good news for patients with moderate-to-severe plaque psoriasis. In only two days two big pharmaceutical companies have issued press releases about…
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Sanofi’s investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes.
The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.
Index Ventures, an early investor in technology hits like Skype and Dropbox, is spinning off its biotech portfolio into a new $1 billion (695 million pounds) business, with backing from drug giants GlaxoSmithKline and Johnson & Johnson .
Premaitha Health, the developer of IONA test, has partnered with Leeds Teaching Hospitals NHS Trust to provide a private NIPT…
Cancer drug maker Roche followed Swiss rival Novartis in disappointing shareholders with a muted forecast for the year, sending its shares lower on Thursday.
By Pamela Barbaglia LONDON (Reuters) – European buyout firm Charterhouse [CHCAP.UL] is preparing for the sale of its Italian generic…
Hikma Pharmaceuticals has prepared a combined Prospectus that contains the formal notice of meeting for the general meeting, to be…